TCTR20190806006招募中2 期
Efficacy and safety of cream containing Centella Asiatica extract for treatment of mild to moderate atopic dermatitis patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1 Years 至 17 Years（—）
- 性别
- All
入选标准
- •1 Male and female
- •2 Age of 1-17 years old
- •3 Patients have been diagnosed as atopic dermatitis by pediatric doctor
- •4 Atopic dermatitis patients with mild to moderate severity (SCORAD score < 40)
- •5 Onset not more than 6 months
- •6 Willing to participate in the trial
排除标准
- •1 History or presence of skin cancer of suspicious lesions
- •2 Participate in another study within the previous 4 weeks.
- •3 Allergy or sensitivity to CA or herbs in the family of Apiaceae
- •4 Applied any moisturizer on the skin lesions
- •Discontinuation criteria
- •1 Skin lesions flare-up in the volunteers (SCORAD score more than 40)
- •2 Secondary infection on-top to the skin
- •3 The occurrence of any severe adverse event
- •4 Applied any moisturizer on the skin lesions
- •5 Loss follow up more than 1 visit, or at the last week
- •6 Loss of follow up more than 1 appointment and at week 4
- •7 Do not desire to continue the trial
研究者
相似试验
尚未招募
3 期
Evaluation of the effectiveness of Raphanus sativus in melasmaIRCT20220223054106N1Tehran University of Medical Sciences25
招募中
3 期
Efficacy and safety evaluation of the cream including Citystem extract and Phytessence extract on reducing skin damage caused by air pollutioSkin damage caused by air pollution.IRCT20161207031288N14Tehran University of Medical Sciences26
已完成
不适用
Effect of Centella asiatica on burning treatmentPartial thickness burning.Burn of first degree of shoulder and upper limb, except wrist and handT20-T25IRCT2013100614915N1Guilan University of Medical Sciences60
已完成
3 期
Effect of whitening cream on melasmaChloasmaIRCT2016121031288N2Jarfandishan-e Navid-e Salamat (Janus) knowledge-based company20
进行中（未招募）
1 期
Assessment of the activity of a new cream containing betamethasone dipropionate at 0.010%, 0.025% and 0.050% versus reference products using a vasoconstriction assay in healthy subjects.Topical treatment of inflammatory dermatosis linked to cutaneous drynessEUCTR2008-007173-20-FRPierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre40